This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinicaltrial data published in the European Journal of Pain. Additional information regarding cannabinoids and pain appears online h ere.
However, there has not been a clinicaltrial assessing the efficacy of cannabis for migraines, at least not until now. Science Alert has announced that the first clinicaltrial for cannabis as a migraine treatment is underway. The First ClinicalTrial for Migraines and Cannabis.
Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. This engagement will build on the strong foundation on Santé, having treated more than 10,000 patients since 2014 under a real-world data protocol. .
IGC”) (NYSE American: IGC) announces today that it has completed Cohort 2 of its Phase 1 clinicaltrial on IGC’s tetrahydrocannabinol (“THC”)-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer’s disease. This Phase 1 trial is currently testing IGC-AD1 for safety.
InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients. For more information, visit www.inmedpharma.com.
The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients.
There is an urgent need for objective, scientifically sound and robust clinicaltrials to support medicinal cannabis and psychedelics (psilocybin, MDMA, LSD, Ketamine). Extensive early phase experience with appropriate safety oversight and early phase clinic.
In a new survey of German patients with Parkinson’s disease, 8% of patients reported using cannabis products. Of these consumers, over half said the drug had a beneficial clinical effect on their condition. Patients can also access CBD products without a prescription through local pharmacies.
Clinicaltrials into cannabis’ potential as an opioid replacement are well underway in South Africa. We are currently recruiting patients, and data-capturing all the questionnaires and feedback from the patients for the live study. Quite frankly, the clinicaltrials couldn’t have come at a better time.
Top 6 ways that Medical Marijuana helps patients with PTSD or other anxiety and mood disorders: Anxiety and Fear Reduction: THC (tetrahydrocannabinol) and CBD (cannabidiol) are the primary cannabinoids in cannabis that interact with the body’s own endocannabinoid system , which plays a role in regulating mood, fear, and stress responses.
(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinicaltrial for IGC-AD1. The results of the clinicaltrial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.
Psilocybin , a psychedelic compound found in a variety of mushrooms, has long been used as a tool to mitigate depression despite the limited amount of research on its efficacy and safety. 233 patients with TRD from 10 countries in North America and Europe received either 1 milligram, 10 milligrams, or 25 milligrams of the COMP360 psilocybin.
The Financing will allow the Company to continue progressing its R&D, clinicaltrials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinicaltrials in early 2022,” said CEO, Josh Bartch. DENVER, Dec.
Are you able to answer your patients’ medical marijuana questions? and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ million medical marijuana patients nationwide. Written by Dr. Meredith Fisher-Corn, MD , Editor-in-Chief at TheAnswerPage.com.
Separate provisions in the bill exclude cannabidiol from the federal definition of marijuana, permit VA doctors to authorize medical cannabis access to qualified patients, and remove undue federal barriers to clinicaltrial research to better assess the safety and efficacy of medical cannabis. NH resident? GA resident?
The most recent one , from June 2021, takes a look at patients using cannabis to relieve pain. Over the prior three years or so, 41,260 RYAH-connected patients reported medical cannabis use for the treatment of pain. RYAH examined reporting from 17,313 such patients over the course of about 3 ½ years.
5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a ClinicalTrial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinicaltrial for INM-755 in healthy volunteers. VANCOUVER, Nov.
5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a ClinicalTrial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinicaltrial for INM-755 in healthy volunteers. VANCOUVER, Nov.
reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). Secondary endpoint of 50% responder rate at 30.4%, consistent with the Marigold Phase 3 CDKL5 deficiency disorder trial results. reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients.
InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients. For more information, visit www.inmedpharma.com.
Studies exploring the effects of cannabis on PTSD have shown promising results in reducing anxiety, improving sleep quality, and enhancing overall mood stability in some patients. While early research is promising, more rigorous studies are needed to establish efficacy, safety, and optimal dosing strategies.
What can the current clinicaltrials tell us? A common theme with cannabis is that more research is needed, so thankfully there are clinicaltrials in the works looking at the therapeutic utility of CBN.
Patients often struggle with symptoms that range from physical discomfort to cognitive impairment. In this article, we explore how medical marijuana for multiple sclerosis symptoms helps patients, with its diverse cannabinoid components, alleviate MS symptoms, and enhance the quality of life for patients.
Recent studies have shown that psilocybin may effectively treat patients with obsessive-compulsive disorder (OCD). And it further reinforces the need to carry out clinicaltrials to determine the safety and efficiency of using psilocybin to treat OCD. In some cases, these patients are prone to depression and suicide.
Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinicaltrials. Beckley Psytech aims to track and improve patient experience through an integrated, digitally-assisted treatment model. June 14, 2022 02:00 AM Eastern Daylight Time.
So just on safety alone, it’s worth using it. I have many patients that want to use cannabis, and they who ask me what product should they get? — and this is probably true in Japan, as well — the time allowed for patient visits has gotten smaller and smaller. You really can’t kill people with cannabis.
– Drug Demonstrates Efficacy and Safety in Advanced Prostate Cancer Patients. – Phase 2 Trial Underway. Highlights from the presentation include: Declining PSA levels in treated patients. Declining circulating tumor cell (CTC) count in treated patients. Phase 2 trial underway. AIkido Pharma Inc.
On top of overwhelming struggles or feelings, patients who have been diagnosed with a terminal illness can face a broad range of both physical and psychological effects. Some patients diagnosed with a terminal illness may begin to feel depressed or physically and mentally lethargic from the effects and symptoms of their disease.
Following the successful experiment into the potential safety and efficacy of using ketamine for Parkinson’s patients, the university proceeded to sign an exclusive licensing partnership with Pharmather Inc. , Studying Ketamine Use for Parkinson’s Disease Patients. and Torsten Falk, Ph.D.,
(NASDAQ: FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is pleased to announce that it has signed an agreement to begin scientific clinicaltrials globally.
It could be argued that the DEA is hesitant for the sake of public safety. The court told the DEA to consider rescheduling cannabis after a slew of patients and proponents claimed the agency was denying them desperately-needed relief. However, it is much more likely that they are too proud to risk being inevitably proven wrong.
Patients around the world are reporting a sharp increase in sleep problems, and physicians have coined the term coronasomnia to describe the phenomenon. Many physicians turn to pharmacologic interventions to help patients sleep. However, there is a tradeoff between effectiveness and safety. Treating Coronasomnia.
11, 2021 (GLOBE NEWSWIRE) COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the second quarter 2021 and gave an update on recent progress across its business. LONDON, Aug. Business highlights.
Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy. Of 272 combined patients, 86% experienced some clinical benefit, and 10% experienced a complete clinical response. improvement in good sleep.
While traditional treatments like antiepileptic drugs exist, they may not always provide adequate relief for all patients. While research is ongoing, some patients have reported remarkable improvements in their seizure control when using MMJ. Some patients have shared their experiences with using MMJ to manage their condition.
assured, “The FDA’s first priority is to protect the health and safety of Americans. It is critical that the FTC take steps to prevent exploitation of patients seeking treatment for substance use disorders.” In its announcement of the warning letters, FDA Principal Deputy Commissioner Amy Abernethy, M.D.,
First Patient Expected to be Enrolled by Q2 of 2022. Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinicaltrial agreement with Altasciences Company, Inc., BERWYN, Pa.–(BUSINESS
Similar to ketamine, psilocybin has shown great promise in clinicaltrials for helping to effectively treat depression and PTSD (and we’ve written about psilocybin several times on this blog, including here and here ). Recently, the decriminalization of psilocybin (by various cities) has been in the news as an emerging medicine.
According to a new study published in the European Journal of Pain, delivering a precise doses of THC via a specialized inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions. 9 -Tetrahydrocannabinol (THC) in patients with chronic pain. 9 -THC: 0.5mg, 1mg, or a placebo. ?
Tetra Bio-Pharma ( TSX: TBP ) ( OTCQB: TBPMF ) ( FRA:JAM1 ) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. For more information visit: www.tetrabiopharma.com.
In November 2018, the legal status of cannabis was changed to allow specialist clinicians to legally prescribe cannabis-derived medicinal products to patients with an exceptional clinical need, following a high-profile media campaign. This would answer questions about safety and efficacy, they said.
“This meta-analysis of pre-clinical stroke studies provides valuable information on the existing, and importantly, missing data on the use of cannabinoids as a potential treatment for stroke patients.
You don’t take that opium poppy and ask a patient to rub it on their lip for morphine. We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds.
For the study researchers with the Nordic Cannabis Research Institute in Denmark reviewed 25 clinicaltrials assessing the safety and efficacy of CBD in various populations. There is moderate-quality evidence that chronic and acute administration of CBD can improve psychotic symptoms in schizophrenia patients.”
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content